Pyridoxine deficiency after solid organ transplant

Summer Van Arsdale, Sarah E. Yost, Chiu-Hsieh Hsu, Mary Meer, Shari Schoentag, Shahid - Habib

Research output: Contribution to journalArticle

Abstract

Objective: Pyridoxine is 1 of 8 B vitamins that assist in a variety of essential functions including immune functions. The purpose of this study was to assess the risk factors associated with low pyridoxine levels in solid organ transplantation recipients. Design: The study cohort was divided into 2 groups: (a) patients with normal pyridoxine levels or (b) patients with low pyridoxine levels. Dietary evaluation and clinical characteristics of all patients, rejection episodes, and immunosuppression were collected. Simple descriptive statistics were used to analyze the overall cohort. Results: Of the 48 patients, 29 (60%) in the study cohort were identified to have low pyridoxine levels. The mean interval between transplantation and pyridoxine level check was 910 days (standard deviation [SD] 456). The mean weight at the time of dietary consultation was 80 kg (SD 20.7). More patients in the deficient group received thymoglobulin for rejection treatment (56% vs 0%; P = .01) and were thymoglobulin recipients (78% vs 10%; odds ratio [OR] = 31.5; 95% confidence interval [CI], 2.35-422.30; P < .01). A strong correlation was identified between thymoglobulin treatment for induction and a low level of pyridoxine (correlation coefficient R = 0.6, P = .004) and between thymoglobulin treatment for rejection and a low pyridoxine level (correlation coefficient R = 0.5, P = .05). Based on multivariate logistic regression analysis, only thymoglobulin treatment (induction or rejection treatment) was significantly associated with low pyridoxine levels (OR = 19.5, 95% CI, 1.01-375.24; P < .05). Conclusions: Low levels of pyridoxine appear to be relatively common, and thymoglobulin treatments are associated with low pyridoxine levels. Prospective studies are needed to confirm and valuate the significance of these findings.

Original languageEnglish (US)
Pages (from-to)251-256
Number of pages6
JournalProgress in Transplantation
Volume27
Issue number3
DOIs
StatePublished - 2017

Fingerprint

Vitamin B 6 Deficiency
Pyridoxine
Transplants
Cohort Studies
Therapeutics
Odds Ratio
Confidence Intervals
Thiamine
Organ Transplantation
Immunosuppression
thymoglobulin

Keywords

  • Intravenous immunoglobulin
  • Nutrition
  • Pyridoxine
  • Thymoglobulin
  • Transplant
  • Vitamin b6

ASJC Scopus subject areas

  • Medicine(all)
  • Transplantation

Cite this

Pyridoxine deficiency after solid organ transplant. / Van Arsdale, Summer; Yost, Sarah E.; Hsu, Chiu-Hsieh; Meer, Mary; Schoentag, Shari; Habib, Shahid -.

In: Progress in Transplantation, Vol. 27, No. 3, 2017, p. 251-256.

Research output: Contribution to journalArticle

Van Arsdale, Summer ; Yost, Sarah E. ; Hsu, Chiu-Hsieh ; Meer, Mary ; Schoentag, Shari ; Habib, Shahid -. / Pyridoxine deficiency after solid organ transplant. In: Progress in Transplantation. 2017 ; Vol. 27, No. 3. pp. 251-256.
@article{0be2d92e27884a86835c87958006aac0,
title = "Pyridoxine deficiency after solid organ transplant",
abstract = "Objective: Pyridoxine is 1 of 8 B vitamins that assist in a variety of essential functions including immune functions. The purpose of this study was to assess the risk factors associated with low pyridoxine levels in solid organ transplantation recipients. Design: The study cohort was divided into 2 groups: (a) patients with normal pyridoxine levels or (b) patients with low pyridoxine levels. Dietary evaluation and clinical characteristics of all patients, rejection episodes, and immunosuppression were collected. Simple descriptive statistics were used to analyze the overall cohort. Results: Of the 48 patients, 29 (60{\%}) in the study cohort were identified to have low pyridoxine levels. The mean interval between transplantation and pyridoxine level check was 910 days (standard deviation [SD] 456). The mean weight at the time of dietary consultation was 80 kg (SD 20.7). More patients in the deficient group received thymoglobulin for rejection treatment (56{\%} vs 0{\%}; P = .01) and were thymoglobulin recipients (78{\%} vs 10{\%}; odds ratio [OR] = 31.5; 95{\%} confidence interval [CI], 2.35-422.30; P < .01). A strong correlation was identified between thymoglobulin treatment for induction and a low level of pyridoxine (correlation coefficient R = 0.6, P = .004) and between thymoglobulin treatment for rejection and a low pyridoxine level (correlation coefficient R = 0.5, P = .05). Based on multivariate logistic regression analysis, only thymoglobulin treatment (induction or rejection treatment) was significantly associated with low pyridoxine levels (OR = 19.5, 95{\%} CI, 1.01-375.24; P < .05). Conclusions: Low levels of pyridoxine appear to be relatively common, and thymoglobulin treatments are associated with low pyridoxine levels. Prospective studies are needed to confirm and valuate the significance of these findings.",
keywords = "Intravenous immunoglobulin, Nutrition, Pyridoxine, Thymoglobulin, Transplant, Vitamin b6",
author = "{Van Arsdale}, Summer and Yost, {Sarah E.} and Chiu-Hsieh Hsu and Mary Meer and Shari Schoentag and Habib, {Shahid -}",
year = "2017",
doi = "10.1177/1526924817715465",
language = "English (US)",
volume = "27",
pages = "251--256",
journal = "Progress in Transplantation",
issn = "1526-9248",
publisher = "InnoVision Communications",
number = "3",

}

TY - JOUR

T1 - Pyridoxine deficiency after solid organ transplant

AU - Van Arsdale, Summer

AU - Yost, Sarah E.

AU - Hsu, Chiu-Hsieh

AU - Meer, Mary

AU - Schoentag, Shari

AU - Habib, Shahid -

PY - 2017

Y1 - 2017

N2 - Objective: Pyridoxine is 1 of 8 B vitamins that assist in a variety of essential functions including immune functions. The purpose of this study was to assess the risk factors associated with low pyridoxine levels in solid organ transplantation recipients. Design: The study cohort was divided into 2 groups: (a) patients with normal pyridoxine levels or (b) patients with low pyridoxine levels. Dietary evaluation and clinical characteristics of all patients, rejection episodes, and immunosuppression were collected. Simple descriptive statistics were used to analyze the overall cohort. Results: Of the 48 patients, 29 (60%) in the study cohort were identified to have low pyridoxine levels. The mean interval between transplantation and pyridoxine level check was 910 days (standard deviation [SD] 456). The mean weight at the time of dietary consultation was 80 kg (SD 20.7). More patients in the deficient group received thymoglobulin for rejection treatment (56% vs 0%; P = .01) and were thymoglobulin recipients (78% vs 10%; odds ratio [OR] = 31.5; 95% confidence interval [CI], 2.35-422.30; P < .01). A strong correlation was identified between thymoglobulin treatment for induction and a low level of pyridoxine (correlation coefficient R = 0.6, P = .004) and between thymoglobulin treatment for rejection and a low pyridoxine level (correlation coefficient R = 0.5, P = .05). Based on multivariate logistic regression analysis, only thymoglobulin treatment (induction or rejection treatment) was significantly associated with low pyridoxine levels (OR = 19.5, 95% CI, 1.01-375.24; P < .05). Conclusions: Low levels of pyridoxine appear to be relatively common, and thymoglobulin treatments are associated with low pyridoxine levels. Prospective studies are needed to confirm and valuate the significance of these findings.

AB - Objective: Pyridoxine is 1 of 8 B vitamins that assist in a variety of essential functions including immune functions. The purpose of this study was to assess the risk factors associated with low pyridoxine levels in solid organ transplantation recipients. Design: The study cohort was divided into 2 groups: (a) patients with normal pyridoxine levels or (b) patients with low pyridoxine levels. Dietary evaluation and clinical characteristics of all patients, rejection episodes, and immunosuppression were collected. Simple descriptive statistics were used to analyze the overall cohort. Results: Of the 48 patients, 29 (60%) in the study cohort were identified to have low pyridoxine levels. The mean interval between transplantation and pyridoxine level check was 910 days (standard deviation [SD] 456). The mean weight at the time of dietary consultation was 80 kg (SD 20.7). More patients in the deficient group received thymoglobulin for rejection treatment (56% vs 0%; P = .01) and were thymoglobulin recipients (78% vs 10%; odds ratio [OR] = 31.5; 95% confidence interval [CI], 2.35-422.30; P < .01). A strong correlation was identified between thymoglobulin treatment for induction and a low level of pyridoxine (correlation coefficient R = 0.6, P = .004) and between thymoglobulin treatment for rejection and a low pyridoxine level (correlation coefficient R = 0.5, P = .05). Based on multivariate logistic regression analysis, only thymoglobulin treatment (induction or rejection treatment) was significantly associated with low pyridoxine levels (OR = 19.5, 95% CI, 1.01-375.24; P < .05). Conclusions: Low levels of pyridoxine appear to be relatively common, and thymoglobulin treatments are associated with low pyridoxine levels. Prospective studies are needed to confirm and valuate the significance of these findings.

KW - Intravenous immunoglobulin

KW - Nutrition

KW - Pyridoxine

KW - Thymoglobulin

KW - Transplant

KW - Vitamin b6

UR - http://www.scopus.com/inward/record.url?scp=85028463709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028463709&partnerID=8YFLogxK

U2 - 10.1177/1526924817715465

DO - 10.1177/1526924817715465

M3 - Article

C2 - 29187089

AN - SCOPUS:85028463709

VL - 27

SP - 251

EP - 256

JO - Progress in Transplantation

JF - Progress in Transplantation

SN - 1526-9248

IS - 3

ER -